• Sulfo-Cy3 NHS Ester for Vascular Assays

  2026-08-17

  Sulfo-Cy3 NHS Ester provides a hydrophilic fluorescent dye strategy for studying the AIBP–LRP2–HDL–miR-223–CXCR4 pathway. This article translates the pathway’s mechanistic findings into practical decisions for protein labeling, uptake assays, tissue imaging, and quantitative fluorescence controls.

• Annexin V-Cy5/DAPI Apoptosis Kit Workflow

  2026-08-16

  The Annexin V-Cy5/DAPI Apoptosis Kit converts phosphatidylserine exposure and membrane integrity into a fast, two-parameter cell-death readout. This guide applies the assay to drug-response studies, including the P2RX1–CaMKII–PI3K/Akt mechanism reported in Ph+ ALL, while emphasizing controls, workflow design, and troubleshooting.

• Amikacin Sulfate: From Mechanism to Translation

  2026-08-15

  A translational strategy for using Amikacin Sulfate in intracellular and granuloma-focused NTM research, integrating bacterial killing, cellular uptake, tissue exposure, and functional-selection thinking from Cas9 inhibitor discovery.

• Deferasirox and Lysosomal Iron Stress

  2026-08-14

  Deferasirox is an oral iron chelator with applications extending from iron overload treatment to mechanistic studies of nutrient stress. This article connects its established iron and mitochondrial effects with TCF25-driven lysosomal adaptation while defining practical assay boundaries.

• γH2AX DNA Damage Detection Kit: FLASH-RT

  2026-08-14

  The γH2AX DNA Damage Detection Kit provides a spatial readout of radiation-induced double-strand break signaling. This article explains how to interpret γ-H2AX foci in FLASH-RT and radiosensitizer studies, including the practical limits of using this DNA damage biomarker γ-H2AX as a standalone endpoint.

• EGCG Nanoparticles Enhance FLASH Radiotherapy

  2026-08-13

  Xu and colleagues developed functionalized, self-assembled EGCG nanoparticles as a radiosensitizing strategy for FLASH radiotherapy. Their findings connect enhanced tumor-cell oxidative and DNA damage with apoptosis, tumor control, and activation of antitumor immune responses, while also highlighting the need for careful mechanistic and safety validation.

• Amikacin Sulfate: NTM Assay Workflows

  2026-08-13

  Build more informative NTM experiments with Amikacin Sulfate by pairing extracellular CFU testing with intracellular dendritic-cell assays and tissue-level pharmacology. This workflow also adapts kidney-injury endpoints from nicotine research to improve interpretation of systemic exposure and toxicity.

• PSPro Enables All-at-Once Spatial Proteome Profiling

  2026-08-12

  Mao and colleagues introduce PSPro, a proximity-labeling workflow that captures cell-type-associated proteomes directly from tissue slices without requiring exhaustive cell-by-cell microdissection. Its application to pancreatic tumor and spleen tissue demonstrates broad protein enrichment and reveals spatial heterogeneity among cancer and immune cell populations.

• DNA Frameworks Improve Enzymatic Oligonucleotide Synthesis

  2026-08-12

  The reference study introduces tetrahedral DNA nanostructures as an ordered interface for improving primer presentation during enzymatic oligonucleotide synthesis. By increasing enzyme accessibility and reducing deletion errors, the framework supported a 60-nucleotide information-storage sequence with a reported stepwise yield of 96.82% and accurate recovery of 15 bytes of text.

• Topotecan HCl: Readouts That Reveal Drug Action

  2026-08-11

  Topotecan HCl research becomes more informative when cytotoxicity is separated from proliferative arrest. This guide applies a dissertation-derived viability framework to dose, timing, assay selection, and translational interpretation of topoisomerase 1 inhibitor experiments.

• METTL17 Links Mitochondrial Translation to CRC Ferroptosis

  2026-08-11

  A 2024 Redox Biology study identifies METTL17 as a mitochondrial RNA-modifying protein that supports mitochondrial translation, ferroptosis resistance, and colorectal cancer progression. Its results connect mitochondrial gene expression with lipid peroxidation and tumor growth, providing a mechanistic framework for testing METTL17-directed combination strategies.

• PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition

  2026-08-10

  A 2024 Theranostics study identifies low PPP2R2A expression as a potential biomarker of CHK1 inhibitor sensitivity in high-grade serous ovarian cancer. Its experiments connect PP2A B55α deficiency with c-Myc-associated replication stress and suggest a strategy for addressing tumors that have become resistant to PARP inhibition.

• Deferasirox A8639 for Reliable Cell Assays

  2026-08-09

  A scenario-based guide to using Deferasirox (SKU A8639) in cell viability, proliferation, and cytotoxicity workflows. It explains concentration selection, mitochondrial assay confounding, nutrient-stress interpretation, solvent handling, and practical product-selection criteria.

• Topotecan HCl: Turning DNA Damage into Translation

  2026-08-08

  A translational framework for using Topotecan HCl as a mechanistic probe of replication-associated DNA damage, tumor-selective vulnerability, treatment schedule, and repair capacity, informed by new findings on selective neuronal loss in neuroinflammation.

• CUX2 Neuron Loss in Neuroinflammation

  2026-08-07

  The reference study identifies accumulated DNA damage and insufficient double-strand break repair as drivers of selective CUX2-positive layer 2/3 neuron loss during neuroinflammation. By integrating human multiple sclerosis tissue, inflammatory and demyelination models, genetic perturbation, and interferon-γ exposure, it links cytokine-associated oxidative stress to cell-type-specific neuronal vulnerability.

16497 records 1/1100 page Next 12345 下5页 Last page